SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium yesterday announced that it was unimpressed with Sanofi-Aventis' Taxotere follow on Jevtana (cabazitaxel) for metastatic prostate cancer. However, it said yes to Merck & Co's Simponi (golimumab) for rheumatoid arthritis and Novartis' Lucentis (ranibizumab) for CRVO.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.